Hepatitis E Clinical Trial
Official title:
An Randomized, Double-blinded Trial of Recombinant Hepatitis E Vaccine (Escherichia Coli) Hecolin® to Evaluate Lot-to-lot Consistency
Verified date | April 2020 |
Source | Xiamen Innovax Biotech Co., Ltd |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study is to evaluate lot-lot consistency of Recombinant Hepatitis E Vaccine (Escherichia Coli) Hecolin®.
Status | Completed |
Enrollment | 360 |
Est. completion date | June 16, 2019 |
Est. primary completion date | June 16, 2019 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 50 Years |
Eligibility |
Inclusion Criteria: - 1. Aged over 18 years old to 50 years old on the day of enrollment 2. Axillary temperature is below than 37.0 ?. 3.Negative serological markers for hepatitis E 4. Judged as healthy and eligible for vaccination by the investigators through a selfreported medical history and some physical examinations. 5. Able to understand this study information and willing to comply with all study requirements. 6. Willing to participate in this study and sign informed consent form. Exclusion Criteria: 1. Pregnancy,breast-feeding or plan to be pregnant in 7 months; 2. Administration of Hepatitis E Vaccine before the study; 3. Participate in any other clinical trial during the study period; 4. Use of any investigational product or non-registered product (drug or vaccine)within 30 days preceding the first dose of the study vaccine or plan to use during the study period; 5. Received immunosuppressed, immunoregulation therapy or corticosteroid systemic therapy for more than 14 days in the 6 months before entry, except local treatment; 6. Administration of any immunoglobulin or blood products within 3 months preceding the first dose of the study vaccine,or plan to use during the study period; 7. Administration of any inactivated vaccines within 14 days preceding the first dose of the study or attenuated live vaccines within 21 days preceding the first dose of the study; 8. Had a fever (axillary temperature over 38°C) within 3 days or acute illness, or use systemic antibiotics or antiviral treatment within 5 days before vaccination; 9. Immunodeficiency (such as HIV carriers), primary disease of important organs, malignant tumor, or any immune disease (such as systemic lupus erythematosus, arthritis pauperum, splenectomy or functional asplenia or other disease which might affect immune response), liver and kidney disease and other chronic disease history; 10. History of allergic disease or history of serious adverse events occurring after vaccination, i.e., allergy,urticaria, dyspnea, angioneurotic edema or abdominal pain. Allergic history to any component of this vaccine. 12. Asthma that needed emergency treatment, hospitalization, oral or intravenous corticosteroid to keep stable in the past two years; 12. Combining another severe internal medicine disease(such as cardiopathy,diabetes and hyperthyroidism) 13. Anormal coagulation function or coagulopathy diagnosed by doctor; 14. Epilepsy(not including alcohol epilepsy within 3 years prior to abstinence and simple epilepsy that do without curing within 3 years prior to the study ) 15. Anomal psychology or mind affecting the individual's ability to obey the study requirement; 16. Other medical, psychological, social or occupational factors that, according to the investigators' judgment,might affect the individual's ability to obey the protocol or sign the informed consent. |
Country | Name | City | State |
---|---|---|---|
China | Dongtai City Center for Disease Control and Prevention | Dongtai | Jiangsu |
Lead Sponsor | Collaborator |
---|---|
Xiamen Innovax Biotech Co., Ltd | Jiangsu Province Centers for Disease Control and Prevention |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Seroconversion rate and GMC of anti-HEV IgG at Month 7. | Measure anti-HEV IgG in serum samples at 7 month to evaluate the immunogenicity of the Hepatitis E vaccine. | 7 months | |
Secondary | Adverse reactions/events of all subjects | Measure solicited local adverse reactions within 7 days after each vaccination; Measure solicited systematic adverse reactions within 7 days after each vaccination; Measure unsolicited adverse reactions within 30 days after vaccination; Measure serious adverse events occurred throughout the study. | up to 7 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02584543 -
A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)(Coadministration With Recombinant Hepatitis B Vaccine)
|
Phase 4 | |
Not yet recruiting |
NCT03488589 -
HEV in Patients With Acute Non-A, Non-B, Non-C Hepatitis in Al-Rajhy University Hospital for Liver
|
||
Completed |
NCT03601221 -
Seroprevalence Hepatitis E Infection in Healthy Blood Donors
|
||
Completed |
NCT03168412 -
A Study on the Recombinant Hepatitis E Vaccine (Escherichia Coli) (Accelerated Vaccination Schedule)
|
Phase 4 | |
Completed |
NCT02189603 -
Phase Ⅳ Clinical Trial of Recombinant Hepatitis E Vaccine(Hecolin®)
|
Phase 4 | |
Completed |
NCT02847507 -
Seroprevalence of Hepatitis E in HIV Positive Patients in Basque Country in 2016 (VIhVhEpb)
|
||
Completed |
NCT02603055 -
A Clinical Trial to Evaluate a Recombinant Hepatitis E Vaccine in Healthy Adults
|
Phase 1 | |
Completed |
NCT02190253 -
Seroprevalence of Hepatitis E in People With an Organ Transplant
|
||
Recruiting |
NCT06457438 -
Molecular Characteristics and Prevalence of Viral Hepatitis E in Human Tissue and Cell Donors
|
N/A | |
Completed |
NCT04670419 -
Morbidity and Mortality of Hepatitis E Virus Infections in Belgium
|
||
Completed |
NCT03282474 -
HepNet Pilot Trial: Multicenter Trial for the Treatment of Chronic Hepatitis E With Sofosbuvir (SofE)
|
Phase 2 | |
Terminated |
NCT02558114 -
Ribavirin for Severe Acute and Chronic Hepatitis E Virus Infection.
|
Phase 4 | |
Recruiting |
NCT06137313 -
Exposure to Hepatitis E Virus in Occitania, France
|
||
Completed |
NCT02964910 -
A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)(the Chronic Hepatitis B Patients )
|
Phase 4 | |
Completed |
NCT01014845 -
Clinical Trial of Recombinant Hepatitis E Vaccine
|
Phase 3 | |
Recruiting |
NCT05976594 -
Long-term Effectiveness of a Recombinant Hepatitis E Vaccine
|
||
Completed |
NCT02417597 -
A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)
|
Phase 4 | |
Completed |
NCT03827395 -
Safety Study of Hepatitis E Vaccine (HEV239)
|
Phase 1 |